Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study

BACKGROUND: This open-label, phase II study aimed to investigate the efficacy and safety of recombinant human endostatin (Rh-endostatin) plus irinotecan/cisplatin as second-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS: Eligible patients received 15mg/m2...

Full description

Bibliographic Details
Main Authors: Chang, J. (Author), Hu, Z. (Author), Sun, S. (Author), Wang, H. (Author), Wang, J. (Author), Wu, X. (Author), Yu, H. (Author), Zhao, X. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
cisplatin
Cisplatin
clinical trial
endostatin
Endostatins
Esophageal Neoplasms
esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma
esophagus tumor
human
Humans
irinotecan
Irinotecan
pathology
phase 2 clinical trial
phase II study
recombinant human endostatin (Rh-endostatin)
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items